Alprazolam Tablet, Orally Disintegrating
NDC Package 0228-4022-11

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Alprazolam tablets is alprazolam is used to treat anxiety and panic disorders. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0228-4022 and is authorized under FDA application ANDA078561.

Identification & Billing

NDC Package Code
0228-4022-11
Package Description
100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
Product Code
11-Digit Billing Format
00228402211
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Alprazolam
Non-Proprietary Name
Alprazolam
Substance Name
Alprazolam
Dosage Form
Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).
DEA Schedule
Schedule IV (CIV) Substances

Regulatory & Marketing

Labeler Name
Actavis Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA078561
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-17-2010
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0228-4022-11 identifies a specific commercial package of 100 tablet, orally disintegrating in 1 bottle of Alprazolam, a human prescription drug labeled by Actavis Pharma, Inc.. This tablet, orally disintegrating is formulated for oral use and contains alprazolam as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actavis Pharma, Inc. on March 17, 2010. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

How is this Actavis Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00228402211. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0228-4022-11
11-Digit CMS (5-4-2)
00228-4022-11

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.